Grey market semaglutide: what the evidence and regulators actually show

What enforcement evidence tells us about unregulated semaglutide

The MHRA's public record on this is more alarming than most buyers realise. A first major enforcement warning came in October 2023, when counterfeit pens labelled as Ozempic and Saxenda were seized in significant quantities. Some contained insulin, a medicine that, injected in the wrong dose by someone without diabetes, can cause a life-threatening hypoglycaemic episode. Enforcement has continued to escalate: by late 2025, UK operations had seized approximately 20 million doses of illegally traded weight-loss medicines, with a street value estimated at around £45 million, and a manufacturing site producing counterfeit tirzepatide pens was raided in Northampton. The breadth of that figure matters, these were not isolated incidents but a sustained pattern across multiple product lines.

Semaglutide (the active ingredient in Wegovy) sits at the centre of that pattern precisely because demand is high and legitimate supply has been constrained. Understanding when Wegovy entered the market and how quickly demand outpaced supply helps explain why grey and black market activity took hold so rapidly. The MHRA's Drug Safety Updates provide the official record of communications on this, the January 2026 update on GLP-1 medicines is particularly relevant for anyone weighing up risks.

The cold-chain problem grey market sellers rarely mention

Semaglutide injections must be stored between 2°C and 8°C until first use. That requirement is not boilerplate, it reflects the biochemical fragility of peptide medicines. A courier operating outside a licensed supply chain has no obligation to maintain that temperature range, and a seller operating via social media or a non-registered platform has no mechanism to prove they did. A pen that has been stored at room temperature for an extended period may look identical to a correctly stored one; the pre-filled injector gives no visible indication of degradation.

Licensed UK pharmacies, including GPhC-registered services like ours, operate within MHRA-regulated dispensing environments and use tracked, temperature-appropriate logistics. That infrastructure is part of what a legitimate prescription covers, not an optional extra. Understanding how the UK semaglutide market is structured helps explain why cutting out the pharmacy entirely doesn't just remove the cost; it removes every safeguard in that chain.

Red flags that take under a minute to check

Most grey market sellers share recognisable patterns. Before purchasing from any online source, spend sixty seconds on the GPhC pharmacy register: a legitimately operating online pharmacy will appear there by name and premises registration number. If a seller is not listed, they are not authorised to dispense Prescription-Only Medicines in the UK. That check alone rules out the majority of illegitimate platforms.

Other patterns worth noting: prices far below the market range for the current period (Eli Lilly raised Mounjaro list prices substantially from September 2025, and semaglutide pricing has followed market dynamics), offers that claim to bypass a prescriber, and discount codes promoted through social media accounts. For anyone wanting to understand the broader competitive landscape, how Wegovy's market share compares with rival treatments puts current pricing pressures into useful context. For detail on what legitimate Wegovy pricing looks like in the UK private market, that page sets out the honest picture. The NHS advises using a GPhC-registered pharmacy and obtaining a valid prescription before any supply, that guidance exists because the alternative is genuinely dangerous, not because regulators are being cautious for form's sake.

What the clinical evidence says about unsupervised GLP-1 use

The trial data for semaglutide at the licensed 2.4mg maintenance dose (including the STEP 1 study published in the New England Journal of Medicine) was generated in a supervised clinical setting, with dose titration managed by healthcare professionals and participants monitored for side effects throughout. The ~15% average weight loss figure often quoted refers to that controlled context. Grey market use collapses the supervision: there is no prescriber managing the titration schedule, no clinical review if side effects emerge, and no adjusted guidance if the person has a contraindication the original seller never screened for. That gap matters most at the edges, for people with a history of pancreatitis, gallbladder disease, or specific gastrointestinal conditions where a GLP-1 medicine may be genuinely unsuitable.

A good overview of how semaglutide works and what the evidence supports is useful background, the mechanism of action, the licensed indications, and the side-effect profile that a prescriber monitors are all part of a picture that grey market supply removes entirely. For anyone reading this who has been considering an unregulated route, that context is worth sitting with before deciding.